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Parenteral nutrition is often used in critically ill patients 
when enteral nutrition is not suﬃ   cient or is not fully 
installed. Lipid emulsions are an integral part of 
parenteral nutrition as they oﬀ  er a high caloric density 
and prevent the fatty liver degeneration of long-term 
carbohydrate-based parenteral nutrition. Beyond use as a 
caloric source, lipids may inﬂ  u  ence the immune response. 
Th   e standard lipid emul  sion is based on soy bean oil (SO) 
supplying n-6 poly  unsaturated fatty acids thought 
necessary to prevent essential fatty acid deﬁ  ciency.  In 
critically ill patients and in animal models, however, a 
negative impact of these lipid emul  sions has been 
described. Barbosa and colleagues now report the eﬀ  ects 
of a new lipid emulsion on clinical and experimental 
parameters in patients with systemic inﬂ  ammatory 
response syndrome and sepsis [1]. How do these eﬀ  ects 
integrate into our current concepts?
Use of SO-based lipid emulsions increases availability 
of free arachidonic acid, the precursor fatty acid of lipid 
mediators in septic patients [2]. A deterioration of the 
PaO2/FiO2 ratio has been attributed to fast infusion 
(6 hours) instead of slow infusion (24 hours) of a SO-
based lipid emulsion in patients with acute respiratory 
distress syndrome due to generation of arachidonic acid-
derived prostaglandins and thromboxane [3]. In a 
simpliﬁ   ed model, sepsis may be described as starting 
with a hyperinﬂ  ammatory phase followed by a phase of 
immune suppression. When used early in septic patients, 
SO-based lipid emulsions have been shown to increase ex 
vivo cytokine generation in a small study [2]. Th  ese  lipid 
emulsions also led to an increased apoptosis of splenic 
lymphocytes in a murine model, amplifying this key 
feature of immune suppres  sion in late sepsis [4]. Recent 
European Society for Parenteral and Enteral Nutrition 
guidelines recommend using other available lipid 
emulsions with a reduced content of n-6 polyunsaturated 
fatty acids instead of SO-based lipid emulsions [5].
Addition of a pure ﬁ  sh oil (FO)-based emulsion to a 
non-FO-containing emulsion or use of FO-containing 
lipid emulsions may oﬀ  er alternative options to provide 
lipids. With this approach a supply of n-3 fatty acids may 
be combined with a reduced deliverance of n-6 lipids. 
Interestingly, the recently discovered n-3 fatty acid-
derived resolvins and protectins are key mediators for the 
active resolution of inﬂ   am  matory processes and their 
application has shown improved outcome in a murine 
model of abdominal sepsis [6]. Results from smaller trials 
and multicenter trials including FO in the parenteral 
nutrition in patients after major surgery herald a good 
clinical beneﬁ  t, including a reduced length of stay (for 
example, [7]).
A larger single-centre trial in 166 critically ill patients 
comparing a lipid emulsion based on SO and medium-
chain triglycerides (LCT/MCT) versus the same 
emulsion supplemented with FO, however, failed to 
detect a clinical beneﬁ  t [8]. Th  is study was planned to 
detect a faster reduction in biomarkers modeled after the 
time course in postoperative patients; however, the 
authors failed to prove a signiﬁ  cant reduction in both 
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to use the lipid emulsions after the initial inﬂ  ammatory 
process was already terminated. All secondary outcome 
parameters – such as, for example, infectious rate, length 
of stay, and mortality – were not signiﬁ  cantly diﬀ  erent.
Th   is study is contrasted by the recent trial of Barbosa 
and coworkers [1]. Th  ey randomized 25 patients with 
systemic inﬂ  ammatory response syndrome and sepsis to 
receive parenteral nutrition with a LCT/MCT emulsion 
or a LCT/MCT/FO lipid emulsion supplied continuously 
over 5 days, demonstrating a highly signiﬁ  cant  faster 
reduction in IL-6 in plasma in the LCT/MCT/FO group. 
In contrast to a previous study by Friesecke and colleagues 
[8], the patients had a higher mortality rate and were 
included earlier, exhibiting high IL-6 plasma concen-
trations at study entry. Barbosa and colleagues could also 
show a signiﬁ  cantly faster improvement of the oxygenation 
parameter, as determined by the PaO2/FiO2 ratio in the 
LCT/MCT/FO group. While other clinical outcome 
parameters were not diﬀ  erent between the two groups, a 
trend for a shorter length of stay in hospital was found.
Keeping in mind the small number of patients included, 
the interesting data of the study are supported by another 
small trial in 40 critically ill patients with severe acute 
pancreatitis [9]. In a double-blind randomized study, 
5  days of parenteral nutrition using a SO-based lipid 
emulsion was compared with SO (80% of the lipid 
component) with additional FO early in the course of the 
disease. Th   e authors reported a signiﬁ  cant reduced need 
for renal replacement therapy and a faster improvement 
in the PaO2/FiO2 ratio in the SO/FO group. Furthermore, 
improved liver function was reported in critically ill 
patients when including a fraction of FO in the parenteral 
nutrition [10], and parenteral nutrition-associated liver 
disease was reversed in a cohort of children receiving 
long-term parenteral nutrition when exchanging a SO-
based lipid emulsion for a FO-based lipid emulsion [11].
What may we conclude from the available data? It 
seems prudent to use lipid emulsions with a reduced 
fraction of n-6 polyunsaturated fatty acids as recom-
mended by the European Society for Parenteral and 
Enteral Nutrition [5]. Th  e  eﬀ  ect of FO seems best when 
used early in critically ill patients. Most studies used 
between 0.1 and 0.2 g/kg/day FO as part of the parenteral 
nutrition. Th   is assumption is supported by the analysis of 
a database in 661 critically ill patients, including patients 
with sepsis, where best outcome data were found in this 
dose range [12]. Th  e promising data from Barbosa and 
colleagues in septic patients should lead to trials 
examining the eﬀ  ects of FO in larger cohorts of patients.
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